Receptos' ozanimod meets maintenance endpoints in UC

Receptos Inc. (NASDAQ:RCPT) gained $9.65 to $167.97 on Thursday after it said 1 mg doses of ozanimod ( RPC1063) met all primary and secondary efficacy endpoints in the maintenance portion of the Phase II TOUCHSTONE trial to treat ulcerative colitis (UC). The company plans to start a Phase III trial in the indication by YE15.

Receptos said a statistically significant proportion of patients who had achieved clinical remission after eight weeks of once-daily doses of 0.5 or 1 mg ozanimod maintained clinical remission at 32 weeks, defined as Mayo score of <=2 points with no individual subscore of >1 point, compared with those receiving placebo (p<0.05). ...